Tagged Articles

Low T 116 articles

Plaintiff awarded $3.2M in AndroGel side effects retrial

An Illinois federal jury awarded an Oregon man $3.2 million, finding drug maker AbbVie Inc., was negligent in its promotion of the testosterone replacement therapy AndroGel. The verdict in the case of plaintiff Jesse Mitchell came after a more than two-week-long trial and resulted in an award of $200,000 in compensatory damages and $3 million in punitive damages. It was the second time a jury deliberated on whether AndroGel caused Mitchell’s heart attack. The first trial ended last summer with a jury finding AndroGel was not the cause of Mitchell’s heart attack and thus no compensatory damages were awarded. But the ... Read More

AbbVie faces fourth testosterone side effects trial

AbbVie Inc. will continue to use deceptive practices to market its testosterone replacement therapy AndroGel unless it is sent a firm message and faces financial pressure, say attorneys for a man who blames his heart attack on the drug. The jury in the fourth bellwether trial against AbbVie in a multidistrict litigation heard testimony alleging testosterone manufacturers did not adequately warn of cardiovascular risks with their testosterone treatments. Jesse Mitchell’s case was the first to go to trial and accuse AbbVie of failing to warn that AndroGel could increase the risk of heart attacks, strokes and blood clots, some of ... Read More

Endocrine Society recommends against prescribing testosterone to older men

The Endocrine Society, the world’s oldest, largest, and most active organization devoted to research on hormones and the clinical practice of endocrinology, is recommending against prescribing testosterone replacement therapy to men 65 years of age and older because the risks and benefits are unclear. The recommendation is part of new guidelines called “Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline,” which was published in The Journal of Clinical Endocrinology & Metabolism. The recommendation is an update to the Society’s 2010 guideline. The recommendation is based on new scientific evidence from large randomized clinical trials. Testosterone treatments ... Read More

Testosterone injections linked to heart risk in older men

Older men who received injections of testosterone were at greater risk of having a heart attack, stroke or unstable angina within a week after receiving the testosterone treatment, according to a new study published in the journal Endocrine Today. However, younger men given testosterone injections were not at increased risk for cardiovascular or cerebrovascular events. “The necessity of injection treatment should be carefully considered before initiating testosterone, particularly in older men,” said J. Bradley Layton, PhD, a pharmacoepidemiologist at RTI Health Solutions in Research Triangle Park, North Carolina. Testosterone replacement therapy is available by prescription in various forms including injections, ... Read More

New trial begins in first testosterone side effects bellwether

A new trial began last week in the case of a man who won a $150 million verdict against Abbvie Inc., after arguing that the company’s testosterone replacement therapy AndroGel caused his heart attack. Plaintiff Jesse Mitchell claims he didn’t know that using the topical testosterone replacement therapy could put him at risk for heart attacks, strokes and blood clots because AbbVie failed to adequately warn consumers or health care professionals. His was the first case to go to trial among thousands in a multidistrict litigation naming several testosterone treatment makers. The first trial ended with a jury award of ... Read More

Judge orders new trial in first testosterone side effects bellwether

U.S. District Judge Matthew Kennelly ordered a new trial in the first bellwether against AbbVie Inc., in a multidistrict litigation accusing testosterone replacement therapy manufacturers of failing to warn of cardiovascular risks, finding that the jury must have misunderstood the issue of causation. Plaintiff Jesse Mitchell claimed AbbVie’s testosterone treatment AndroGel was not adequately tested to better understand its cardiovascular risks. Despite this, the company aggressively marketed the drug for the off-label treatment of a made-up condition they called Low T. The jury awarded Mitchell $150 million in punitive damages, finding the company misrepresented its testosterone therapy. But the jury ... Read More

Three drug makers reach tentative settlement in testosterone side effects MDL

Three manufacturers of testosterone replacement therapies among several in a multidistrict litigation accusing the companies of failing to warn consumers about cardiovascular risks with their products, have notified an Illinois federal judge that they have reached a tentative deal to settle the cases in which they are named. U.S. District Judge Matthew Kennelly told the manufacturers – Endo Pharmaceuticals Inc., Auxilium Pharmaceuticals LLC and GlaxoSmithKline LLC – that he would place a 45-day stay on the cases against them while the details of the settlement are worked out. He also told the remaining defendants – including AbbVie Inc., and Actavis ... Read More

Patient asks that new AndroGel side effects trial be on all claims

Jesse Mitchell asked an Illinois federal court to order a new trial on all his claims against testosterone manufacturer AbbVie Inc., instead of just one claim in the first bellwether in a multidistrict litigation accusing makers of testosterone replacement therapies of misrepresenting their products and failing to warn that their treatments were linked to cardiovascular risks. Jurors in that case did not find Abbie’s AndroGel as the cause of Mitchell’s heart attack, but did find the company guilty of fraudulently misrepresenting the testosterone treatment through alleged off-label marketing. As a result, they awarded Mitchell no compensatory damages, but did award ... Read More

Testosterone lawsuits blame makers for failing to warn of drug’s risks

AbbVie won the latest testosterone side effects lawsuit alleging its testosterone replacement therapy AndroGel caused a man to suffer debilitating blood clots, but the two previous plaintiffs wins with verdicts totaling nearly $300 million suggest the fight has only just begun. AbbVie’s AndroGel has enjoyed the lion’s share of sales in the once-booming testosterone replacement therapy market. The hormone treatment was approved by the Food and Drug Administration (FDA) in 2000 for the treatment of hypogonadism, a condition in which there is a testosterone deficiency due to a genetic defect, illness or trauma. But AbbVie began aggressively promoting the drug ... Read More

Several testosterone side effects trials scheduled through 2019

Three trials involving testosterone side effects have taken place in 2017 and another 10 or 11 cases are scheduled to be tried through 2019, due to U.S. District Judge Matthew Kennelly’s interest in ensuring all plaintiffs and defendants have the benefit of timely bellwethers. The multidistrict litigation is consolidated in the U.S. District Court for the Northern District of Illinois and names a handful of testosterone manufacturers including AbbVie Inc., Eli Lilly & Co., and Auxilium Pharmaceuticals Inc. There are also state cases by Illinois residents against AbbVie. The Cook County judge is coordinating with Judge Kennelly on those cases. ... Read More